Arecor Therapeutics Management
Management criteria checks 2/4
Arecor Therapeutics' CEO is Sarah Howell, appointed in Jun 2015, has a tenure of 9.5 years. total yearly compensation is £439.00K, comprised of 59.2% salary and 40.8% bonuses, including company stock and options. directly owns 2.3% of the company’s shares, worth €726.79K. The average tenure of the management team and the board of directors is 1.7 years and 7.3 years respectively.
Key information
Sarah Howell
Chief executive officer
UK£439.0k
Total compensation
| CEO salary percentage | 59.2% |
| CEO tenure | 9.5yrs |
| CEO ownership | 2.3% |
| Management average tenure | 1.7yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£9m |
| Mar 31 2024 | n/a | n/a | -UK£9m |
| Dec 31 2023 | UK£439k | UK£260k | -UK£9m |
| Sep 30 2023 | n/a | n/a | -UK£9m |
| Jun 30 2023 | n/a | n/a | -UK£9m |
| Mar 31 2023 | n/a | n/a | -UK£9m |
| Dec 31 2022 | UK£421k | UK£250k | -UK£9m |
| Sep 30 2022 | n/a | n/a | -UK£8m |
| Jun 30 2022 | n/a | n/a | -UK£7m |
| Mar 31 2022 | n/a | n/a | -UK£7m |
| Dec 31 2021 | UK£343k | UK£218k | -UK£6m |
Compensation vs Market: Sarah's total compensation ($USD552.02K) is about average for companies of similar size in the German market ($USD466.27K).
Compensation vs Earnings: Sarah's compensation has increased whilst the company is unprofitable.
CEO
Sarah Howell (49 yo)
9.5yrs
Tenure
UK£439,000
Compensation
Dr. Sarah Jennifer Howell, Ph.D. has been the Chief Executive Officer of Arecor Therapeutics PLC since June 2015. Having joined in 2011 as Chief Operating Officer and Executive Director. During her time at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.5yrs | UK£439.00k | 2.3% € 726.8k | |
| Interim Chief Financial Officer | less than a year | no data | no data | |
| Chief Scientific Officer | 17.9yrs | no data | no data | |
| Senior Vice President of Development | 1.4yrs | no data | no data | |
| Chief Business Officer | 1.7yrs | no data | no data |
1.7yrs
Average Tenure
Experienced Management: 6UI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.7yrs | UK£439.00k | 2.3% € 726.8k | |
| Independent Non-Executive Director | 3.6yrs | UK£40.00k | 0.051% € 16.1k | |
| Non-Executive Director | no data | UK£35.00k | 0.48% € 152.2k | |
| Non-Executive Chairman | 8.3yrs | UK£80.00k | 0.59% € 187.5k | |
| Independent Non-Executive Director | 7.3yrs | UK£35.00k | 0.31% € 96.9k | |
| Member of Global Diabetes Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Global Diabetes Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Global Diabetes Scientific Advisory Board | 7.3yrs | no data | no data | |
| Independent Non-Executive Director | 3.6yrs | UK£40.00k | 0.072% € 22.8k |
7.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: 6UI's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 00:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arecor Therapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dr Julie | Panmure Liberum |
| Julie Simmonds | Panmure Liberum |
| Julie Simmonds | Panmure Liberum Historic (Panmure Gordon) |